Search the Newsreel

Exagen (XGN) Stock Gets Fair Value Boost As Analysts Weigh Growth And Execution

BRIEF-Exagen Inc. Q2 Revenue USD 19.941 Million Vs. IBES Estimate USD 17.8 Million

Exagen Inc. reported its Q2 revenue at $19.941 million, surpassing the IBES estimate of $17.8 million. The brief financial update indicates a stronger-than-expected performance for the company in the second quarter.

Exagen Q2 Earnings Call Highlights

Exagen Inc (XGN) reported record quarterly revenue of $19.9 million in Q2 2026, marking a 16% year-over-year increase, driven by record AVISE test volume and Pharma Services revenue. The company also significantly narrowed its adjusted EBITDA loss to $0.1 million and raised its full-year …

Earnings call transcript: Exagen tops Q2 2026 estimates, shares jump 20%

Exagen (XGN) reported strong Q2 2026 results, surpassing Wall Street expectations with record revenue of $19.9 million and narrowing its adjusted EBITDA loss to $0.1 million. The autoimmune-testing company also raised its full-year 2026 revenue guidance to $72 million-$75 million, driven by increased test …

Is Exagen Inc (XGN) Worth the Price After Q2 Earnings? Revenue Hits $19.9M but GF Score Indicates 56.3% Overvalued

Exagen Inc (XGN) reported Q2 2026 revenue of $19.9 million, surpassing analyst estimates and marking a 16% increase year-over-year, with a reduced net loss of $3.2 million. Despite strong growth and improved operational efficiency, GuruFocus rates the stock as 56.3% overvalued at its current …

Exagen (NASDAQ:XGN) Announces Quarterly Earnings Results

Exagen Inc. (NASDAQ: XGN) lifts Q2 2026 revenue to $19.9M

Exagen Inc. reported a significant increase in Q2 2026 revenue to $19.9 million, up from $17.2 million a year earlier, primarily driven by its AVISE® CTD autoimmune diagnostic test. The company narrowed its net loss to $3.2 million and improved its operating loss to …

EXAGEN INC. Q2 2026: Revenue $19.94M, EPS $(0.13) — 10-Q Summary

EXAGEN INC. (XGN) reported its Q2 2026 financial results, showing revenue of $19.94 million and a diluted EPS of $(0.13). The company achieved a narrower net loss of $3.2 million compared to $4.44 million in the prior year, driven by improved margins, higher test …

Exagen Q2 2026 slides: record revenue, stock surges 36%

Exagen Inc. reported record revenue of $19.9 million for Q2 2026, marking 16% year-over-year growth and exceeding analyst expectations. The company's stock surged 35.9% following the announcement, driven by strong quarterly performance and raised full-year guidance. Exagen is nearing profitability, with adjusted EBITDA loss …

Exagen Reports Record Second-Quarter Revenue and Narrows Losses, Raises Full-Year 2026 Guidance

Exagen (XGN) announced record second-quarter 2026 revenue of $19.9 million, a 16% increase year-over-year. Despite a net loss of $3.2 million, the company raised its full-year 2026 revenue guidance to $72 million to $75 million. Insider trading data shows recent sales by executives, while …

Exagen Inc. Reports Second Quarter 2026 Financial Results

Exagen Inc. (Nasdaq: XGN) reported record total revenue of $19.9 million for the second quarter of 2026, a 16% increase year-over-year, and narrowed its adjusted EBITDA loss to $0.1 million. The company achieved a trailing twelve-month average selling price (ASP) of $446 for its …

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Exagen Inc. (XGN) reported a Q2 loss of $0.13 per share, exceeding the Zacks Consensus Estimate of a $0.19 loss and outperforming the prior year's loss of $0.18 per share. The company's revenues reached $19.94 million, surpassing the consensus estimate by 10.58% and the …

Exagen (XGN) Stock Jumps On Record Revenue But Profit Timing Remains Unclear

Exagen Inc. (NASDAQ:XGN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Exagen Inc (XGN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Exagen Inc (XGN), highlighting its current valuation score of 7.83 and its ranking within the Healthcare Providers & Services industry. It details the company's P/E ratio, noting its current value relative to recent highs and lows. The …

Exagen Inc (XGN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Exagen Inc (XGN), detailing its volatility, financial risk, and investment risk. It highlights the company's current risk assessment score, beta value, and various return and volatility metrics over different periods. The assessment also considers the neutral effect …

Exagen's Aug. 11 fireside chat will be live and archived

Exagen Inc. (Nasdaq: XGN) announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on August 11, 2026. The company will host a Fireside Chat at 8:30 a.m. ET, with live and archived webcasts available on its …

Exagen Inc. to Participate in Upcoming Investor Conference

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced its management will participate in the Canaccord Genuity 46th Annual Growth Conference. The company will host a Fireside Chat on August 11, 2026, at 8:30 am ET, which will be available via webcast …

Exagen Inc (XGN) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Exagen Inc (XGN), which currently holds a financial score of 6.98, ranking 55th out of 75 in the Healthcare Providers & Services industry. The company shows stable financial status and low operating efficiency, with its latest quarterly …

Exagen Inc (XGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Exagen Inc (XGN), detailing its price momentum score of 4.06 and noting its current trading range between support at $3.93 and resistance at $4.99. It includes a breakdown of various technical indicators (MACD, RSI, STOCH, ATR, CCI, …

Exagen Inc (XGN) Income Statement

This article provides the quarterly and annual income statement for Exagen Inc (XGN), detailing financial performance metrics such as total revenue, cost of revenue, operating expenses, and net income. It presents a historical overview of these financials, along with year-over-year changes, allowing users to …

Exagen Inc (XGN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Exagen Inc's (XGN) shareholder structure, listing major shareholders and their proportionate holdings, as well as the types of shareholders involved. It also includes institutional shareholding data over various reporting periods, showing changes in the number of institutions …

Exagen Inc (XGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Exagen Inc (XGN), categorizing its revenue by business segments such as Commercial, Government, and Client, along with an "Other" category. It presents the revenue in USD for an unspecified financial year, showing the monetary amount and …

Exagen Inc (XGN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Exagen Inc.'s (XGN) dividend and stock split history. It notes that the company has distributed a total of $0.00 in dividends over the past five years and currently has no dividend data available. The article also includes current …

Exagen Inc (XGN) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Exagen Inc (XGN), covering operating, investing, and financing activities from 2013 to 2026. It also includes key financial figures such as net income, capital expenditures, and free cash flow, explaining how these …

XGN|Exagen Inc|Price:4.680|Chg%:-0.270

Exagen Inc. (XGN) is trading at $4.680, down 5.45% at market close. The company specializes in autoimmune diagnostics and has shown strong revenue growth, with analysts giving it a 'Buy' rating and a target price of $8.571. Its fundamentals are deemed healthy, and its …

Exagen Inc (XGN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Exagen Inc (XGN) has an earnings forecast score of 8.57, ranking it 11th in the Healthcare Providers & Services industry. Analysts project an average price target of $15.00 for XGN, with a high of $18.00 and a low of $12.00, suggesting a 73.16% upside. …

Exagen to Announce Second Quarter Financial Results on August 4, 2026

Exagen Inc. (Nasdaq: XGN) will release its financial results for the quarter ended June 30, 2026, before the market opens on Tuesday, August 4, 2026. President and CEO John Aballi and CFO Jeff Black will host a conference call and webcast to discuss the …

Exagen: A Small Diagnostics Company Approaching An Inflection Point (NASDAQ:XGN)

Exagen stock stabilizes as autoimmune testing revenue grows and losses narrow

Exagen Inc. (XGN) stock is showing signs of stabilization as the autoimmune diagnostics company reports growing revenue and narrowing losses. The company is focused on expanding the adoption of its specialized tests among rheumatologists and other specialists, improving operating leverage as revenue grows, and …

Exagen schedules 8:30 a.m. call to review second-quarter results

Exagen (XGN) will release its financial results for the quarter ended June 30, 2026, before the market opens on Tuesday, August 4, 2026. The company will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) on the same day to discuss the …

Enterprise value to revenue forward of Exagen Inc. – NASDAQ:XGN

Exagen Q1 Earnings Call Highlights